Pfizer Reports Quarterly Revenue of $16.6 Billion
Date: 3 November 2026
Pfizer announced its third-quarter 2026 financial results, reporting revenue of approximately $16.6 billion, which remained broadly comparable with the same period last year. Solid contribution from newly launched and acquired products drove strong underlying growth.
🧬 Financial & Guidance Highlights
Revenue Performance: Reported quarterly revenue reached $16.6 billion, matching prior-year levels.
Non-COVID Growth: Operational revenue grew ~7% when excluding COVID-related products.
Raised Revenue Outlook: Full-year revenue guidance was upgraded to $62–64 billion.
Improved EPS Guidance: Adjusted diluted EPS guidance was increased to $2.95–$3.05.
📈 Strategic & Leadership Updates
Pipeline Impact: Launched and acquired products contributed significantly to operational growth.
Executive Leadership: The company announced the appointment of a new Chief Financial Officer.
Strategic Priorities: Oncology, immunology, and obesity-related treatments remain key focus areas.
Economic Spillover: Performance highlights the role of pharmaceutical innovation and global healthcare investment.
Let’s discuss below! 👇
Think wider and think beyond—“BONC it” on BONC Network!














